ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 107,900 shares, an increase of 9.3% from the May 31st total of 98,700 shares. Based on an average trading volume of 52,600 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.2% of the shares of the stock are short sold.
ABIVAX Société Anonyme Trading Up 2.6 %
ABIVAX Société Anonyme stock opened at $13.56 on Tuesday. The stock has a 50-day moving average price of $14.07 and a 200 day moving average price of $13.36. ABIVAX Société Anonyme has a 52 week low of $7.99 and a 52 week high of $17.02. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.23.
Institutional Trading of ABIVAX Société Anonyme
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $13,630,000. Capstone Investment Advisors LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $618,000. Ghisallo Capital Management LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $642,000. Commodore Capital LP purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $20,277,000. Finally, Blackstone Inc. purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $25,345,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Research Report on ABIVAX Société Anonyme
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
- Five stocks we like better than ABIVAX Société Anonyme
- Conference Calls and Individual Investors
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Are Trending Stocks? Trending Stocks Explained
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.